• mail us help@statsmarketresearch.com
  • Int'l (+1)-646-781-7170
  • Asia: (+91)-916-916-4321

TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Global Selective Cox-2 Inhibitors Market Insights and Forecast to 2028

Global Selective Cox-2 Inhibitors Market Insights and Forecast to 2028

  • Category:Life Sciences
  • Published on : 24 May 2022
  • Pages :128
  • Formats:
  • Report Code:SMR-7106910
OfferClick for best price

Best Price: $3920

Selective Cox-2 Inhibitors market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Selective Cox-2 Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type

  • Meloxicam
  • Celecoxib
  • Etoricoxib
  • Imrecoxib
  • Etodolac
  • Parecoxib
  • Other

Segment by Application

  • Rheumatoid Arthritis
  • Osteoarthritis
  • Spondylosis Chronica Ankylopoietica
  • Other

By Company

  • Boehringer-Ingelheim
  • TerSera Therapeutics
  • Iroko Pharmaceuticals
  • Apotex
  • Yung Shin Pharmaceutical
  • Breckenridge Pharmaceutical
  • Meda Pharmaceuticals
  • Cipla
  • Glenmark Pharmaceuticals
  • Teva
  • PuraCap Pharmaceutical
  • Almirall Limited
  • Lupin Pharmaceuticals
  • Aurobindo Pharma
  • Pfizer
  • Mylan
  • Takeda
  • Bayer
  • Novacap
  • Abbott
  • Geri-Care
  • Perrigo
  • Kopran
  • Merck
  • Hengrui pharmaceutical
  • Kelun Group
  • Qilu Pharmaceutical
  • Taro Pharmaceuticals

By Region

  • North America
  • United States
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Russia
  • Nordic Countries
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia
  • Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
  • Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

The information for each competitor/Company Profile includes:

  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis 

The content of the study subjects includes a total of 15 chapters:

Chapter 1, describes Selective Cox2 Inhibitors product scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2, profiles the top manufacturers of Selective Cox2 Inhibitors, with price, sales, revenue, and global market share of Selective Cox2 Inhibitors from 2019 to 2022.

Chapter 3, the Selective Cox2 Inhibitors competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Selective Cox2 Inhibitors breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.

Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Selective Cox2 Inhibitors market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of Selective Cox2 Inhibitors.

Chapter 13, 14, and 15, to describe Selective Cox2 Inhibitors sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Key Indicators Analysed:

  • Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
  • Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
  • Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
  • Opportunities and Drivers: Identifying the Growing Demands and New Technology
  • Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Reasons to Purchase this Report:

  • Estimates 2022-2027 2021-2025 Selective Cox2 Inhibitors Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
  • Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
  • Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
  • Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • 1-year analyst support, along with the data support in excel format.

Research Methodology:

The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

TABLE OF CONTENTS

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Selective Cox-2 Inhibitors Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Meloxicam
1.2.3 Celecoxib
1.2.4 Etoricoxib
1.2.5 Imrecoxib
1.2.6 Etodolac
1.2.7 Parecoxib
1.2.8 Other
1.3 Market by Application
1.3.1 Global Selective Cox-2 Inhibitors Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Rheumatoid Arthritis
1.3.3 Osteoarthritis
1.3.4 Spondylosis Chronica Ankylopoietica
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Selective Cox-2 Inhibitors Market Perspective (2017-2028)
2.2 Selective Cox-2 Inhibitors Growth Trends by Region
2.2.1 Selective Cox-2 Inhibitors Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Selective Cox-2 Inhibitors Historic Market Size by Region (2017-2022)
2.2.3 Selective Cox-2 Inhibitors Forecasted Market Size by Region (2023-2028)
2.3 Selective Cox-2 Inhibitors Market Dynamics
2.3.1 Selective Cox-2 Inhibitors Industry Trends
2.3.2 Selective Cox-2 Inhibitors Market Drivers
2.3.3 Selective Cox-2 Inhibitors Market Challenges
2.3.4 Selective Cox-2 Inhibitors Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Selective Cox-2 Inhibitors Players by Revenue
3.1.1 Global Top Selective Cox-2 Inhibitors Players by Revenue (2017-2022)
3.1.2 Global Selective Cox-2 Inhibitors Revenue Market Share by Players (2017-2022)
3.2 Global Selective Cox-2 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Selective Cox-2 Inhibitors Revenue
3.4 Global Selective Cox-2 Inhibitors Market Concentration Ratio
3.4.1 Global Selective Cox-2 Inhibitors Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Selective Cox-2 Inhibitors Revenue in 2021
3.5 Selective Cox-2 Inhibitors Key Players Head office and Area Served
3.6 Key Players Selective Cox-2 Inhibitors Product Solution and Service
3.7 Date of Enter into Selective Cox-2 Inhibitors Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Selective Cox-2 Inhibitors Breakdown Data by Type
4.1 Global Selective Cox-2 Inhibitors Historic Market Size by Type (2017-2022)
4.2 Global Selective Cox-2 Inhibitors Forecasted Market Size by Type (2023-2028)
5 Selective Cox-2 Inhibitors Breakdown Data by Application
5.1 Global Selective Cox-2 Inhibitors Historic Market Size by Application (2017-2022)
5.2 Global Selective Cox-2 Inhibitors Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Selective Cox-2 Inhibitors Market Size (2017-2028)
6.2 North America Selective Cox-2 Inhibitors Market Size by Type
6.2.1 North America Selective Cox-2 Inhibitors Market Size by Type (2017-2022)
6.2.2 North America Selective Cox-2 Inhibitors Market Size by Type (2023-2028)
6.2.3 North America Selective Cox-2 Inhibitors Market Share by Type (2017-2028)
6.3 North America Selective Cox-2 Inhibitors Market Size by Application
6.3.1 North America Selective Cox-2 Inhibitors Market Size by Application (2017-2022)
6.3.2 North America Selective Cox-2 Inhibitors Market Size by Application (2023-2028)
6.3.3 North America Selective Cox-2 Inhibitors Market Share by Application (2017-2028)
6.4 North America Selective Cox-2 Inhibitors Market Size by Country
6.4.1 North America Selective Cox-2 Inhibitors Market Size by Country (2017-2022)
6.4.2 North America Selective Cox-2 Inhibitors Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Selective Cox-2 Inhibitors Market Size (2017-2028)
7.2 Europe Selective Cox-2 Inhibitors Market Size by Type
7.2.1 Europe Selective Cox-2 Inhibitors Market Size by Type (2017-2022)
7.2.2 Europe Selective Cox-2 Inhibitors Market Size by Type (2023-2028)
7.2.3 Europe Selective Cox-2 Inhibitors Market Share by Type (2017-2028)
7.3 Europe Selective Cox-2 Inhibitors Market Size by Application
7.3.1 Europe Selective Cox-2 Inhibitors Market Size by Application (2017-2022)
7.3.2 Europe Selective Cox-2 Inhibitors Market Size by Application (2023-2028)
7.3.3 Europe Selective Cox-2 Inhibitors Market Share by Application (2017-2028)
7.4 Europe Selective Cox-2 Inhibitors Market Size by Country
7.4.1 Europe Selective Cox-2 Inhibitors Market Size by Country (2017-2022)
7.4.2 Europe Selective Cox-2 Inhibitors Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Selective Cox-2 Inhibitors Market Size (2017-2028)
8.2 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Type
8.2.1 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Selective Cox-2 Inhibitors Market Share by Type (2017-2028)
8.3 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Application
8.3.1 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Selective Cox-2 Inhibitors Market Share by Application (2017-2028)
8.4 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Region
8.4.1 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Selective Cox-2 Inhibitors Market Size (2017-2028)
9.2 Latin America Selective Cox-2 Inhibitors Market Size by Type
9.2.1 Latin America Selective Cox-2 Inhibitors Market Size by Type (2017-2022)
9.2.2 Latin America Selective Cox-2 Inhibitors Market Size by Type (2023-2028)
9.2.3 Latin America Selective Cox-2 Inhibitors Market Share by Type (2017-2028)
9.3 Latin America Selective Cox-2 Inhibitors Market Size by Application
9.3.1 Latin America Selective Cox-2 Inhibitors Market Size by Application (2017-2022)
9.3.2 Latin America Selective Cox-2 Inhibitors Market Size by Application (2023-2028)
9.3.3 Latin America Selective Cox-2 Inhibitors Market Share by Application (2017-2028)
9.4 Latin America Selective Cox-2 Inhibitors Market Size by Country
9.4.1 Latin America Selective Cox-2 Inhibitors Market Size by Country (2017-2022)
9.4.2 Latin America Selective Cox-2 Inhibitors Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Selective Cox-2 Inhibitors Market Size (2017-2028)
10.2 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Type
10.2.1 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Selective Cox-2 Inhibitors Market Share by Type (2017-2028)
10.3 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Application
10.3.1 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Selective Cox-2 Inhibitors Market Share by Application (2017-2028)
10.4 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Country
10.4.1 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Boehringer-Ingelheim
11.1.1 Boehringer-Ingelheim Company Details
11.1.2 Boehringer-Ingelheim Business Overview
11.1.3 Boehringer-Ingelheim Selective Cox-2 Inhibitors Introduction
11.1.4 Boehringer-Ingelheim Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
11.1.5 Boehringer-Ingelheim Recent Developments
11.2 TerSera Therapeutics
11.2.1 TerSera Therapeutics Company Details
11.2.2 TerSera Therapeutics Business Overview
11.2.3 TerSera Therapeutics Selective Cox-2 Inhibitors Introduction
11.2.4 TerSera Therapeutics Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
11.2.5 TerSera Therapeutics Recent Developments
11.3 Iroko Pharmaceuticals
11.3.1 Iroko Pharmaceuticals Company Details
11.3.2 Iroko Pharmaceuticals Business Overview
11.3.3 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Introduction
11.3.4 Iroko Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
11.3.5 Iroko Pharmaceuticals Recent Developments
11.4 Apotex
11.4.1 Apotex Company Details
11.4.2 Apotex Business Overview
11.4.3 Apotex Selective Cox-2 Inhibitors Introduction
11.4.4 Apotex Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
11.4.5 Apotex Recent Developments
11.5 Yung Shin Pharmaceutical
11.5.1 Yung Shin Pharmaceutical Company Details
11.5.2 Yung Shin Pharmaceutical Business Overview
11.5.3 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Introduction
11.5.4 Yung Shin Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
11.5.5 Yung Shin Pharmaceutical Recent Developments
11.6 Breckenridge Pharmaceutical
11.6.1 Breckenridge Pharmaceutical Company Details
11.6.2 Breckenridge Pharmaceutical Business Overview
11.6.3 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Introduction
11.6.4 Breckenridge Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
11.6.5 Breckenridge Pharmaceutical Recent Developments
11.7 Meda Pharmaceuticals
11.7.1 Meda Pharmaceuticals Company Details
11.7.2 Meda Pharmaceuticals Business Overview
11.7.3 Meda Pharmaceuticals Selective Cox-2 Inhibitors Introduction
11.7.4 Meda Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
11.7.5 Meda Pharmaceuticals Recent Developments
11.8 Cipla
11.8.1 Cipla Company Details
11.8.2 Cipla Business Overview
11.8.3 Cipla Selective Cox-2 Inhibitors Introduction
11.8.4 Cipla Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
11.8.5 Cipla Recent Developments
11.9 Glenmark Pharmaceuticals
11.9.1 Glenmark Pharmaceuticals Company Details
11.9.2 Glenmark Pharmaceuticals Business Overview
11.9.3 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Introduction
11.9.4 Glenmark Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
11.9.5 Glenmark Pharmaceuticals Recent Developments
11.10 Teva
11.10.1 Teva Company Details
11.10.2 Teva Business Overview
11.10.3 Teva Selective Cox-2 Inhibitors Introduction
11.10.4 Teva Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
11.10.5 Teva Recent Developments
11.11 PuraCap Pharmaceutical
11.11.1 PuraCap Pharmaceutical Company Details
11.11.2 PuraCap Pharmaceutical Business Overview
11.11.3 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Introduction
11.11.4 PuraCap Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
11.11.5 PuraCap Pharmaceutical Recent Developments
11.12 Almirall Limited
11.12.1 Almirall Limited Company Details
11.12.2 Almirall Limited Business Overview
11.12.3 Almirall Limited Selective Cox-2 Inhibitors Introduction
11.12.4 Almirall Limited Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
11.12.5 Almirall Limited Recent Developments
11.13 Lupin Pharmaceuticals
11.13.1 Lupin Pharmaceuticals Company Details
11.13.2 Lupin Pharmaceuticals Business Overview
11.13.3 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Introduction
11.13.4 Lupin Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
11.13.5 Lupin Pharmaceuticals Recent Developments
11.14 Aurobindo Pharma
11.14.1 Aurobindo Pharma Company Details
11.14.2 Aurobindo Pharma Business Overview
11.14.3 Aurobindo Pharma Selective Cox-2 Inhibitors Introduction
11.14.4 Aurobindo Pharma Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
11.14.5 Aurobindo Pharma Recent Developments
11.15 Pfizer
11.15.1 Pfizer Company Details
11.15.2 Pfizer Business Overview
11.15.3 Pfizer Selective Cox-2 Inhibitors Introduction
11.15.4 Pfizer Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
11.15.5 Pfizer Recent Developments
11.16 Mylan
11.16.1 Mylan Company Details
11.16.2 Mylan Business Overview
11.16.3 Mylan Selective Cox-2 Inhibitors Introduction
11.16.4 Mylan Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
11.16.5 Mylan Recent Developments
11.17 Takeda
11.17.1 Takeda Company Details
11.17.2 Takeda Business Overview
11.17.3 Takeda Selective Cox-2 Inhibitors Introduction
11.17.4 Takeda Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
11.17.5 Takeda Recent Developments
11.18 Bayer
11.18.1 Bayer Company Details
11.18.2 Bayer Business Overview
11.18.3 Bayer Selective Cox-2 Inhibitors Introduction
11.18.4 Bayer Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
11.18.5 Bayer Recent Developments
11.19 Novacap
11.19.1 Novacap Company Details
11.19.2 Novacap Business Overview
11.19.3 Novacap Selective Cox-2 Inhibitors Introduction
11.19.4 Novacap Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
11.19.5 Novacap Recent Developments
11.20 Abbott
11.20.1 Abbott Company Details
11.20.2 Abbott Business Overview
11.20.3 Abbott Selective Cox-2 Inhibitors Introduction
11.20.4 Abbott Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
11.20.5 Abbott Recent Developments
11.21 Geri-Care
11.21.1 Geri-Care Company Details
11.21.2 Geri-Care Business Overview
11.21.3 Geri-Care Selective Cox-2 Inhibitors Introduction
11.21.4 Geri-Care Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
11.21.5 Geri-Care Recent Developments
11.22 Perrigo
11.22.1 Perrigo Company Details
11.22.2 Perrigo Business Overview
11.22.3 Perrigo Selective Cox-2 Inhibitors Introduction
11.22.4 Perrigo Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
11.22.5 Perrigo Recent Developments
11.23 Kopran
11.23.1 Kopran Company Details
11.23.2 Kopran Business Overview
11.23.3 Kopran Selective Cox-2 Inhibitors Introduction
11.23.4 Kopran Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
11.23.5 Kopran Recent Developments
11.24 Merck
11.24.1 Merck Company Details
11.24.2 Merck Business Overview
11.24.3 Merck Selective Cox-2 Inhibitors Introduction
11.24.4 Merck Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
11.24.5 Merck Recent Developments
11.25 Hengrui pharmaceutical
11.25.1 Hengrui pharmaceutical Company Details
11.25.2 Hengrui pharmaceutical Business Overview
11.25.3 Hengrui pharmaceutical Selective Cox-2 Inhibitors Introduction
11.25.4 Hengrui pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
11.25.5 Hengrui pharmaceutical Recent Developments
11.26 Kelun Group
11.26.1 Kelun Group Company Details
11.26.2 Kelun Group Business Overview
11.26.3 Kelun Group Selective Cox-2 Inhibitors Introduction
11.26.4 Kelun Group Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
11.26.5 Kelun Group Recent Developments
11.27 Qilu Pharmaceutical
11.27.1 Qilu Pharmaceutical Company Details
11.27.2 Qilu Pharmaceutical Business Overview
11.27.3 Qilu Pharmaceutical Selective Cox-2 Inhibitors Introduction
11.27.4 Qilu Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
11.27.5 Qilu Pharmaceutical Recent Developments
11.28 Taro Pharmaceuticals?
11.28.1 Taro Pharmaceuticals? Company Details
11.28.2 Taro Pharmaceuticals? Business Overview
11.28.3 Taro Pharmaceuticals? Selective Cox-2 Inhibitors Introduction
11.28.4 Taro Pharmaceuticals? Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
11.28.5 Taro Pharmaceuticals? Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

LIST OF TABLES & FIGURES

List of Tables
Table 1. Global Selective Cox-2 Inhibitors Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Meloxicam
Table 3. Key Players of Celecoxib
Table 4. Key Players of Etoricoxib
Table 5. Key Players of Imrecoxib
Table 6. Key Players of Etodolac
Table 7. Key Players of Parecoxib
Table 8. Key Players of Other
Table 9. Global Selective Cox-2 Inhibitors Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 10. Global Selective Cox-2 Inhibitors Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 11. Global Selective Cox-2 Inhibitors Market Size by Region (2017-2022) & (US$ Million)
Table 12. Global Selective Cox-2 Inhibitors Market Share by Region (2017-2022)
Table 13. Global Selective Cox-2 Inhibitors Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 14. Global Selective Cox-2 Inhibitors Market Share by Region (2023-2028)
Table 15. Selective Cox-2 Inhibitors Market Trends
Table 16. Selective Cox-2 Inhibitors Market Drivers
Table 17. Selective Cox-2 Inhibitors Market Challenges
Table 18. Selective Cox-2 Inhibitors Market Restraints
Table 19. Global Selective Cox-2 Inhibitors Revenue by Players (2017-2022) & (US$ Million)
Table 20. Global Selective Cox-2 Inhibitors Revenue Share by Players (2017-2022)
Table 21. Global Top Selective Cox-2 Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Selective Cox-2 Inhibitors as of 2021)
Table 22. Ranking of Global Top Selective Cox-2 Inhibitors Companies by Revenue (US$ Million) in 2021
Table 23. Global 5 Largest Players Market Share by Selective Cox-2 Inhibitors Revenue (CR5 and HHI) & (2017-2022)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Selective Cox-2 Inhibitors Product Solution and Service
Table 26. Date of Enter into Selective Cox-2 Inhibitors Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Selective Cox-2 Inhibitors Market Size by Type (2017-2022) & (US$ Million)
Table 29. Global Selective Cox-2 Inhibitors Revenue Market Share by Type (2017-2022)
Table 30. Global Selective Cox-2 Inhibitors Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 31. Global Selective Cox-2 Inhibitors Revenue Market Share by Type (2023-2028)
Table 32. Global Selective Cox-2 Inhibitors Market Size by Application (2017-2022) & (US$ Million)
Table 33. Global Selective Cox-2 Inhibitors Revenue Share by Application (2017-2022)
Table 34. Global Selective Cox-2 Inhibitors Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 35. Global Selective Cox-2 Inhibitors Revenue Share by Application (2023-2028)
Table 36. North America Selective Cox-2 Inhibitors Market Size by Type (2017-2022) & (US$ Million)
Table 37. North America Selective Cox-2 Inhibitors Market Size by Type (2023-2028) & (US$ Million)
Table 38. North America Selective Cox-2 Inhibitors Market Size by Application (2017-2022) & (US$ Million)
Table 39. North America Selective Cox-2 Inhibitors Market Size by Application (2023-2028) & (US$ Million)
Table 40. North America Selective Cox-2 Inhibitors Market Size by Country (2017-2022) & (US$ Million)
Table 41. North America Selective Cox-2 Inhibitors Market Size by Country (2023-2028) & (US$ Million)
Table 42. Europe Selective Cox-2 Inhibitors Market Size by Type (2017-2022) & (US$ Million)
Table 43. Europe Selective Cox-2 Inhibitors Market Size by Type (2023-2028) & (US$ Million)
Table 44. Europe Selective Cox-2 Inhibitors Market Size by Application (2017-2022) & (US$ Million)
Table 45. Europe Selective Cox-2 Inhibitors Market Size by Application (2023-2028) & (US$ Million)
Table 46. Europe Selective Cox-2 Inhibitors Market Size by Country (2017-2022) & (US$ Million)
Table 47. Europe Selective Cox-2 Inhibitors Market Size by Country (2023-2028) & (US$ Million)
Table 48. Asia Pacific Selective Cox-2 Inhibitors Market Size by Type (2017-2022) & (US$ Million)
Table 49. Asia Pacific Selective Cox-2 Inhibitors Market Size by Type (2023-2028) & (US$ Million)
Table 50. Asia Pacific Selective Cox-2 Inhibitors Market Size by Application (2017-2022) & (US$ Million)
Table 51. Asia Pacific Selective Cox-2 Inhibitors Market Size by Application (2023-2028) & (US$ Million)
Table 52. Asia Pacific Selective Cox-2 Inhibitors Market Size by Region (2017-2022) & (US$ Million)
Table 53. Asia Pacific Selective Cox-2 Inhibitors Market Size by Region (2023-2028) & (US$ Million)
Table 54. Latin America Selective Cox-2 Inhibitors Market Size by Type (2017-2022) & (US$ Million)
Table 55. Latin America Selective Cox-2 Inhibitors Market Size by Type (2023-2028) & (US$ Million)
Table 56. Latin America Selective Cox-2 Inhibitors Market Size by Application (2017-2022) & (US$ Million)
Table 57. Latin America Selective Cox-2 Inhibitors Market Size by Application (2023-2028) & (US$ Million)
Table 58. Latin America Selective Cox-2 Inhibitors Market Size by Country (2017-2022) & (US$ Million)
Table 59. Latin America Selective Cox-2 Inhibitors Market Size by Country (2023-2028) & (US$ Million)
Table 60. Middle East and Africa Selective Cox-2 Inhibitors Market Size by Type (2017-2022) & (US$ Million)
Table 61. Middle East and Africa Selective Cox-2 Inhibitors Market Size by Type (2023-2028) & (US$ Million)
Table 62. Middle East and Africa Selective Cox-2 Inhibitors Market Size by Application (2017-2022) & (US$ Million)
Table 63. Middle East and Africa Selective Cox-2 Inhibitors Market Size by Application (2023-2028) & (US$ Million)
Table 64. Middle East and Africa Selective Cox-2 Inhibitors Market Size by Country (2017-2022) & (US$ Million)
Table 65. Middle East and Africa Selective Cox-2 Inhibitors Market Size by Country (2023-2028) & (US$ Million)
Table 66. Boehringer-Ingelheim Company Details
Table 67. Boehringer-Ingelheim Business Overview
Table 68. Boehringer-Ingelheim Selective Cox-2 Inhibitors Product
Table 69. Boehringer-Ingelheim Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
Table 70. Boehringer-Ingelheim Recent Developments
Table 71. TerSera Therapeutics Company Details
Table 72. TerSera Therapeutics Business Overview
Table 73. TerSera Therapeutics Selective Cox-2 Inhibitors Product
Table 74. TerSera Therapeutics Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
Table 75. TerSera Therapeutics Recent Developments
Table 76. Iroko Pharmaceuticals Company Details
Table 77. Iroko Pharmaceuticals Business Overview
Table 78. Iroko Pharmaceuticals Selective Cox-2 Inhibitors Product
Table 79. Iroko Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
Table 80. Iroko Pharmaceuticals Recent Developments
Table 81. Apotex Company Details
Table 82. Apotex Business Overview
Table 83. Apotex Selective Cox-2 Inhibitors Product
Table 84. Apotex Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
Table 85. Apotex Recent Developments
Table 86. Yung Shin Pharmaceutical Company Details
Table 87. Yung Shin Pharmaceutical Business Overview
Table 88. Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Product
Table 89. Yung Shin Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
Table 90. Yung Shin Pharmaceutical Recent Developments
Table 91. Breckenridge Pharmaceutical Company Details
Table 92. Breckenridge Pharmaceutical Business Overview
Table 93. Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Product
Table 94. Breckenridge Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
Table 95. Breckenridge Pharmaceutical Recent Developments
Table 96. Meda Pharmaceuticals Company Details
Table 97. Meda Pharmaceuticals Business Overview
Table 98. Meda Pharmaceuticals Selective Cox-2 Inhibitors Product
Table 99. Meda Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
Table 100. Meda Pharmaceuticals Recent Developments
Table 101. Cipla Company Details
Table 102. Cipla Business Overview
Table 103. Cipla Selective Cox-2 Inhibitors Product
Table 104. Cipla Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
Table 105. Cipla Recent Developments
Table 106. Glenmark Pharmaceuticals Company Details
Table 107. Glenmark Pharmaceuticals Business Overview
Table 108. Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Product
Table 109. Glenmark Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
Table 110. Glenmark Pharmaceuticals Recent Developments
Table 111. Teva Company Details
Table 112. Teva Business Overview
Table 113. Teva Selective Cox-2 Inhibitors Product
Table 114. Teva Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
Table 115. Teva Recent Developments
Table 116. PuraCap Pharmaceutical Company Details
Table 117. PuraCap Pharmaceutical Business Overview
Table 118. PuraCap Pharmaceutical Selective Cox-2 Inhibitors Product
Table 119. PuraCap Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
Table 120. PuraCap Pharmaceutical Recent Developments
Table 121. Almirall Limited Company Details
Table 122. Almirall Limited Business Overview
Table 123. Almirall Limited Selective Cox-2 Inhibitors Product
Table 124. Almirall Limited Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
Table 125. Almirall Limited Recent Developments
Table 126. Lupin Pharmaceuticals Company Details
Table 127. Lupin Pharmaceuticals Business Overview
Table 128. Lupin Pharmaceuticals Selective Cox-2 Inhibitors Product
Table 129. Lupin Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
Table 130. Lupin Pharmaceuticals Recent Developments
Table 131. Aurobindo Pharma Company Details
Table 132. Aurobindo Pharma Business Overview
Table 133. Aurobindo Pharma Selective Cox-2 Inhibitors Product
Table 134. Aurobindo Pharma Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
Table 135. Aurobindo Pharma Recent Developments
Table 136. Pfizer Company Details
Table 137. Pfizer Business Overview
Table 138. Pfizer Selective Cox-2 Inhibitors Product
Table 139. Pfizer Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
Table 140. Pfizer Recent Developments
Table 141. Mylan Company Details
Table 142. Mylan Business Overview
Table 143. Mylan Selective Cox-2 Inhibitors Product
Table 144. Mylan Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
Table 145. Mylan Recent Developments
Table 146. Takeda Company Details
Table 147. Takeda Business Overview
Table 148. Takeda Selective Cox-2 Inhibitors Product
Table 149. Takeda Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
Table 150. Takeda Recent Developments
Table 151. Bayer Company Details
Table 152. Bayer Business Overview
Table 153. Bayer Selective Cox-2 Inhibitors Product
Table 154. Bayer Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
Table 155. Bayer Recent Developments
Table 156. Novacap Company Details
Table 157. Novacap Business Overview
Table 158. Novacap Selective Cox-2 Inhibitors Product
Table 159. Novacap Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
Table 160. Novacap Recent Developments
Table 161. Abbott Company Details
Table 162. Abbott Business Overview
Table 163. Abbott Selective Cox-2 Inhibitors Product
Table 164. Abbott Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
Table 165. Abbott Recent Developments
Table 166. Geri-Care Company Details
Table 167. Geri-Care Business Overview
Table 168. Geri-Care Selective Cox-2 Inhibitors Product
Table 169. Geri-Care Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
Table 170. Geri-Care Recent Developments
Table 171. Perrigo Company Details
Table 172. Perrigo Business Overview
Table 173. Perrigo Selective Cox-2 Inhibitors Product
Table 174. Perrigo Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
Table 175. Perrigo Recent Developments
Table 176. Kopran Company Details
Table 177. Kopran Business Overview
Table 178. Kopran Selective Cox-2 Inhibitors Product
Table 179. Kopran Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
Table 180. Kopran Recent Developments
Table 181. Merck Company Details
Table 182. Merck Business Overview
Table 183. Merck Selective Cox-2 Inhibitors Product
Table 184. Merck Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
Table 185. Merck Recent Developments
Table 186. Hengrui pharmaceutical Company Details
Table 187. Hengrui pharmaceutical Business Overview
Table 188. Hengrui pharmaceutical Selective Cox-2 Inhibitors Product
Table 189. Hengrui pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
Table 190. Hengrui pharmaceutical Recent Developments
Table 191. Kelun Group Company Details
Table 192. Kelun Group Business Overview
Table 193. Kelun Group Selective Cox-2 Inhibitors Product
Table 194. Kelun Group Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
Table 195. Kelun Group Recent Developments
Table 196. Qilu Pharmaceutical Company Details
Table 197. Qilu Pharmaceutical Business Overview
Table 198. Qilu Pharmaceutical Selective Cox-2 Inhibitors Product
Table 199. Qilu Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
Table 200. Qilu Pharmaceutical Recent Developments
Table 201. Taro Pharmaceuticals? Company Details
Table 202. Taro Pharmaceuticals? Business Overview
Table 203. Taro Pharmaceuticals? Selective Cox-2 Inhibitors Product
Table 204. Taro Pharmaceuticals? Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
Table 205. Taro Pharmaceuticals? Recent Developments
Table 206. Research Programs/Design for This Report
Table 207. Key Data Information from Secondary Sources
Table 208. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Selective Cox-2 Inhibitors Market Share by Type: 2021 VS 2028
Figure 2. Meloxicam Features
Figure 3. Celecoxib Features
Figure 4. Etoricoxib Features
Figure 5. Imrecoxib Features
Figure 6. Etodolac Features
Figure 7. Parecoxib Features
Figure 8. Other Features
Figure 9. Global Selective Cox-2 Inhibitors Market Share by Application: 2021 VS 2028
Figure 10. Rheumatoid Arthritis Case Studies
Figure 11. Osteoarthritis Case Studies
Figure 12. Spondylosis Chronica Ankylopoietica Case Studies
Figure 13. Other Case Studies
Figure 14. Selective Cox-2 Inhibitors Report Years Considered
Figure 15. Global Selective Cox-2 Inhibitors Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 16. Global Selective Cox-2 Inhibitors Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 17. Global Selective Cox-2 Inhibitors Market Share by Region: 2021 VS 2028
Figure 18. Global Selective Cox-2 Inhibitors Market Share by Players in 2021
Figure 19. Global Top Selective Cox-2 Inhibitors Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Selective Cox-2 Inhibitors as of 2021)
Figure 20. The Top 10 and 5 Players Market Share by Selective Cox-2 Inhibitors Revenue in 2021
Figure 21. North America Selective Cox-2 Inhibitors Market Size YoY (2017-2028) & (US$ Million)
Figure 22. North America Selective Cox-2 Inhibitors Market Size Market Share by Type (2017-2028)
Figure 23. North America Selective Cox-2 Inhibitors Market Size Market Share by Application (2017-2028)
Figure 24. North America Selective Cox-2 Inhibitors Market Size Share by Country (2017-2028)
Figure 25. United States Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. Canada Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Europe Selective Cox-2 Inhibitors Market Size YoY (2017-2028) & (US$ Million)
Figure 28. Europe Selective Cox-2 Inhibitors Market Size Market Share by Type (2017-2028)
Figure 29. Europe Selective Cox-2 Inhibitors Market Size Market Share by Application (2017-2028)
Figure 30. Europe Selective Cox-2 Inhibitors Market Size Share by Country (2017-2028)
Figure 31. Germany Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. France Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. U.K. Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Italy Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Russia Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Nordic Countries Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Asia-Pacific Selective Cox-2 Inhibitors Market Size YoY (2017-2028) & (US$ Million)
Figure 38. Asia Pacific Selective Cox-2 Inhibitors Market Size Market Share by Type (2017-2028)
Figure 39. Asia Pacific Selective Cox-2 Inhibitors Market Size Market Share by Application (2017-2028)
Figure 40. Asia Pacific Selective Cox-2 Inhibitors Market Size Share by Region (2017-2028)
Figure 41. China Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Japan Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. South Korea Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Southeast Asia Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 45. India Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 46. Australia Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 47. Latin America Selective Cox-2 Inhibitors Market Size YoY (2017-2028) & (US$ Million)
Figure 48. Latin America Selective Cox-2 Inhibitors Market Size Market Share by Type (2017-2028)
Figure 49. Latin America Selective Cox-2 Inhibitors Market Size Market Share by Application (2017-2028)
Figure 50. Latin America Selective Cox-2 Inhibitors Market Size Share by Country (2017-2028)
Figure 51. Mexico Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 52. Brazil Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 53. Middle East & Africa Selective Cox-2 Inhibitors Market Size YoY (2017-2028) & (US$ Million)
Figure 54. Middle East and Africa Selective Cox-2 Inhibitors Market Size Market Share by Type (2017-2028)
Figure 55. Middle East and Africa Selective Cox-2 Inhibitors Market Size Market Share by Application (2017-2028)
Figure 56. Middle East and Africa Selective Cox-2 Inhibitors Market Size Share by Country (2017-2028)
Figure 57. Turkey Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 58. Saudi Arabia Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 59. UAE Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 60. Boehringer-Ingelheim Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
Figure 61. TerSera Therapeutics Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
Figure 62. Iroko Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
Figure 63. Apotex Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
Figure 64. Yung Shin Pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
Figure 65. Breckenridge Pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
Figure 66. Meda Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
Figure 67. Cipla Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
Figure 68. Glenmark Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
Figure 69. Teva Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
Figure 70. PuraCap Pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
Figure 71. Almirall Limited Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
Figure 72. Lupin Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
Figure 73. Aurobindo Pharma Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
Figure 74. Pfizer Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
Figure 75. Mylan Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
Figure 76. Takeda Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
Figure 77. Bayer Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
Figure 78. Novacap Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
Figure 79. Abbott Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
Figure 80. Geri-Care Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
Figure 81. Perrigo Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
Figure 82. Kopran Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
Figure 83. Merck Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
Figure 84. Hengrui pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
Figure 85. Kelun Group Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
Figure 86. Qilu Pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
Figure 87. Taro Pharmaceuticals? Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
Figure 88. Bottom-up and Top-down Approaches for This Report
Figure 89. Data Triangulation
Figure 90. Key Executives Interviewed

PURCHASE OPTIONS

USD GBP EURO YEN Single User Price
USD GBP EURO YEN Multi User Price
USD GBP EURO YEN Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount